Pertuzumab

Pertuzumab is a targeted cancer therapy used mainly to treat HER2-positive breast cancer. It is a type of monoclonal antibody designed to bind specifically to the HER2 protein on cancer cells, which promotes their growth. By attaching to HER2, pertuzumab blocks signals that encourage tumor growth and helps the immune system recognize and attack the cancer. Often used in combination with other treatments like chemotherapy, it improves outcomes by stopping the cancer’s progress and reducing the chance of recurrence. Pertuzumab is administered intravenously and is an important option in advanced or early-stage HER2-positive breast cancer management.